Literature DB >> 21733506

Importance of timing of gestational exposure to methotrexate for its teratogenic effects when used in setting of misdiagnosis of ectopic pregnancy.

Sarah H Poggi1, Alessandro Ghidini.   

Abstract

OBJECTIVE: To report a case of embryopathy due to misadministration of methotrexate in the setting of suspected ectopic pregnancy that resulted in a different pattern of malformations than is typically seen with methotrexate.
DESIGN: Case report.
SETTING: Community hospital. PATIENT(S): A 30-year-old primigravida women exposed to methotrexate (50 mg/m(2)) at 5 6/7 weeks' gestation. INTERVENTION(S): The patient underwent amniocentesis because of abnormal results at the first-trimester genetic screening (low levels of pregnancy associated plasma protein A and hCG) and fetal echocardiogram because of single umbilical artery. MAIN OUTCOME MEASURE(S): Fetal anomalies. RESULT(S): The fetus was found to have a single umbilical artery, tetralogy of Fallot, and a "horseshoe lung," despite administration of high doses of folic acid. The pregnancy ultimately ended with fetal demise at 30 weeks. CONCLUSION(S): As medical management of ectopic pregnancy becomes more common, practitioners should be cautious about the potential teratogenic effects in unrecognized intrauterine pregnancies and be able to diagnose the myriad defects, including cardiac anomalies, that could result from such exposure.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733506     DOI: 10.1016/j.fertnstert.2011.06.014

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

Review 1.  Fetal Physiologically Based Pharmacokinetic Models: Systems Information on the Growth and Composition of Fetal Organs.

Authors:  Khaled Abduljalil; Masoud Jamei; Trevor N Johnson
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

2.  In response to "In utero exposure to methotrexate and risk of congenital malformations".

Authors:  April L Dawson; Tiffany Riehle-Colarusso; Jennita Reefhuis; J Fernando Arena
Journal:  Am J Med Genet A       Date:  2015-05-10       Impact factor: 2.802

3.  Methotrexate for management of twin pregnancy with complete hydatidiform mole and co-existing live fetus: A case report.

Authors:  Mhd Moamen Al Mouallem; Nazih Tawashi; Ieman AlAWAD; Fatima Alawad; Majd Hanna
Journal:  Int J Surg Case Rep       Date:  2022-06-18

4.  Extremity Findings of Methotrexate Embryopathy.

Authors:  Esperanza Mantilla-Rivas; Ashleigh Brennan; Agnes Goldrich; Justin R Bryant; Albert K Oh; Gary F Rogers
Journal:  Hand (N Y)       Date:  2019-09-22

5.  Maternal exposure to methotrexate and birth defects: a population-based study.

Authors:  April L Dawson; Tiffany Riehle-Colarusso; Jennita Reefhuis; J Fernando Arena
Journal:  Am J Med Genet A       Date:  2014-06-04       Impact factor: 2.802

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.